COGTHealthcareMid-Cap
Cogent Biosciences, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Cogent Biosciences, Inc. (COGT), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are COGT insiders buying or selling?
Cogent Biosciences, Inc. insiders reported 5 open-market buys ($46.0M) and 14 sells ($383.6M) across 19 Form 4 filings — a net selling position of $337.6M.
Source: SEC EDGAR Form 4
Key Statistics (as of Apr 1, 2026)
Total Form 4 filings
19
SEC EDGAR
Insider filers
9
Insider buys (5)
$46.0M
Insider sells (14)
$383.6M
Insider sentiment
Net sellingNet insider flow of $337.6M in net selling.
Recent COGT insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Fairmount Funds Management LLC | Director | Sale | 7.0M | $34.66 | $242.6M |
| Jan 23, 2026 | Fairmount Funds Management LLC | Director | Sale | 3.5M | $36.40 | $127.4M |
| Dec 30, 2025 | Evan Kearns | Chief Legal Officer | Sale | 65.0K | $38.70 | $2.5M |
| Dec 30, 2025 | John L. Green | Chief Financial Officer | Sale | 77.0K | $38.68 | $3.0M |
| Dec 30, 2025 | Jessica Sachs | Chief Medical Officer | Sale | 82.6K | $38.70 | $3.2M |
| Dec 30, 2025 | John Edward Robinson | Chief Scientific Officer | Sale | 90.0K | $38.74 | $3.5M |
| Jul 14, 2025 | Fairmount Funds Management LLC | Director | Purchase | 2.8M | $9.00 | $25.0M |
| Jan 15, 2025 | Cole Pinnow | Chief Commercial Officer | Purchase | 43.8K | $7.60 | $332.4K |
| Jun 13, 2023 | Fairmount Funds Management LLC | Other, 10% Owner | Purchase | 800.0K | $12.00 | $9.6M |
| Jun 21, 2022 | Fairmount Funds Management LLC | Other, 10% Owner | Purchase | 1.2M | $8.25 | $9.9M |
| Apr 29, 2021 | John L. Green | Chief Financial Officer | Sale | 17.8K | $8.86 | $157.8K |
| Oct 8, 2020 | Dario Campana | 10% Owner | Sale | 2.0M | $0.39 | $788.4K |
| Aug 18, 2020 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Purchase | 451.0K | $2.52 | $1.1M |
| Mar 26, 2019 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $4.12 | $47.3K |
| Feb 26, 2019 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $4.25 | $48.9K |
| Dec 29, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $4.05 | $46.5K |
| Nov 27, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $7.00 | $80.4K |
| Oct 29, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $8.46 | $97.2K |
| Sep 26, 2018 | Seth Ettenberg | Chief Scientific Officer | Sale | 11.5K | $12.47 | $143.2K |
Showing the 19 most recent of 19 Form 4 filings for Cogent Biosciences, Inc..
Most active COGT insiders
- Seth Ettenberg6 filings
- Fairmount Funds Management LLC5 filings
- John L. Green2 filings
- Cole Pinnow1 filing
- Dario Campana1 filing
Ask anything about COGT insider activity
Use Trabud's AI agent to query Cogent Biosciences, Inc.'s Form 4 history in plain English — "Show me COGT CEO purchases this year" or compare it against any other ticker.
Open the AI agentCOGT insider trading FAQ
Are Cogent Biosciences, Inc. insiders buying or selling?
Across 19 SEC Form 4 filings, Cogent Biosciences, Inc. (COGT) insiders reported 5 open-market purchases totaling $46.0M and 14 sales totaling $383.6M. That is a net selling position of $337.6M.
How many insiders trade COGT stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Cogent Biosciences, Inc.. The most recent filing was accepted on Apr 1, 2026.
Where does Trabud get COGT insider trading data?
All COGT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.